Palomar Q2 Beat Doesn't Resolve Core Underwriting and Reinsurance Uncertainty

What happened

Palomar reported second-quarter adjusted net income of $63.8 million, or $2.36 per share, handily beating the prior-year $48.5 million and affirming strong near-term earnings power. The press release, however, omitted critical segment-level metrics—particularly loss ratios for the newly added Surety & Credit unit and any update on purchase accounting—leaving the market without the granular data needed to evaluate the diversification strategy. While the headline numbers appear consistent with management’s guidance for modest Gray Surety accretion in 2026, the absence of reserve adequacy commentary and reinsurance renewal details keeps the structural risks firmly in focus. With the company now carrying a $450 million covenant-bearing facility, any underwriting deterioration would quickly translate into equity-relevant stress, making these disclosures pivotal. Investors must therefore wait for upcoming quarterly filings and the 6/1/2026 reinsurance outcome before de-risking the Wait thesis.

Implication

The Q2 results do not alter the cautious stance, as the market still lacks visibility on surety loss emergence and the cost of reinsurance protection in a hardening market. Until those unknowns are resolved, the stock is likely to trade within the $105–$130 range, with downside risk from adverse reserve development or covenant pressure. Investors should use any strength toward $145 to reduce exposure and consider entry only if the price revisits $105 or segment results confirm sub-25% surety loss ratios. The next two quarters will be decisive: successful navigation of these catalysts could lift the stock to the base-case $130, while any misstep would justify a move toward the $95 bear case.

Thesis delta

The Q2 earnings release does not materially change the investment thesis; strong headline numbers are unsurprising given the preannounced guidance, and the lack of segment detail means the market is still flying blind on surety underwriting quality and reinsurance renewal economics. We maintain our Wait rating as the risk/reward remains balanced until those catalysts are resolved.